<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03176498</url>
  </required_header>
  <id_info>
    <org_study_id>SCLnow-IMIMH-01</org_study_id>
    <nct_id>NCT03176498</nct_id>
  </id_info>
  <brief_title>Human Umbilical Cord Mesenchymal Stem Cell Therapy for Cerebral Infarction Patients in Convalescent Period.</brief_title>
  <official_title>The Effects of Human Umbilical Cord Mesenchymal Stem Cell Therapy on Neurological Function for Cerebral Infarction Patients in Convalescent Period.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sclnow Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sclnow Biotechnology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind study. Human umbilical cord mesenchymal stem cells
      (hUC-MSC) will be treated on cerebral infarction patients, and evaluates their neurological
      function of convalescent period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      40 participants will be selected based on eligibility criteria and collected information,
      then, randomly separated into two groups. All participants will sign informed consent form,
      monitor vital signs, laboratory examination (CT/MRI, blood routine examination, urine routine
      examination, liver function, renal function, etc.), NIHSS, Fugl-Meyer analysis (FMA) 0-3 days
      before treatment. All of them will receive basic treatment with Aspirin Enteric-coated
      Tablets and Atorvastatin Calcium. And experimental group will treat with hUC-MSC, control
      group with placebo (normal saline) on the 7th and 14th day. After the treatment, investigator
      will follow-up, monitor vital signs, laboratory examination, NIHSS, FMA analysis on 2 weeks,
      1 month, and 6 months after the treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2017</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Motor function analysis</measure>
    <time_frame>6 months</time_frame>
    <description>Based on Activity of Daily Living Scale (ADL) to analysis efficacy of cell treatment.The score of patient with upper limb &gt;60, and total score &gt;90 is considered good recovery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurological deficits analysis</measure>
    <time_frame>6 months</time_frame>
    <description>According to Chinese scale of clinical neurologic deficit to analysis, the result as follow:
Excellent: after treatment, patient with consciousness, and clinical symptoms improved;
Effective: vital signs and main symptoms in remission;
Inefficient: no obvious improvement or condition worsened.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limb motor function analysis</measure>
    <time_frame>6 months</time_frame>
    <description>Using fugl-meyer assessment evaluate motor function. Mild movement disorder: 96 - 99; Moderate movement disorder: 85 - 95; Obvious movement disorder: 50 - 84; Serious movement disorder: &lt; 50</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index analysis</measure>
    <time_frame>6 months</time_frame>
    <description>Obvious effective: Barthel Index score between 96 - 99, patient with self care ability.
Effective:Barthel Index score between 70 - 89, patient with condition improved. Invalid: The effect do not meet above standards.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cerebral Infarction</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Basic medication：Aspirin Enteric-coated Tablets &amp; Atorvastatin Calcium； Allogeneic umbilical cord mesenchymal stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Basic medication：Aspirin Enteric-coated Tablets &amp; Atorvastatin Calcium; Placebo：saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic umbilical cord mesenchymal stem cell</intervention_name>
    <description>Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin Enteric-coated Tablets &amp; Atorvastatin Calcium</intervention_name>
    <description>Aspirin Enteric-coated Tablets, 0.1g/d by mouth; Atorvastatin Calcium, 20mg/d by mouth.</description>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  proved cerebral infarction by CT or MRI.

          -  no cerebrovascular disease before

          -  signed informed consent form

        Exclusion Criteria:

          -  serious body and intracranial lesions (tumor, infection, etc.)

          -  patients repeated cerebral infarction attacks

          -  multi-foci of cerebral infarction

          -  history of drug dependence and mental disease

          -  disturbance of consciousness and non-compliance patients

          -  subjects who are HIV positive

          -  pregnant or lactation

          -  donor: HIV infected, Active hepatitis B/C infected, Syphilis antibody positive

          -  subjects/ donor: alcoholism, drug addicts or mental disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wulan</last_name>
    <role>Study Director</role>
    <affiliation>Inner Mongolia International Mongolian Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lei Guo, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Jilin University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Guo</last_name>
    <phone>861064368977</phone>
    <email>georgeguo@sclnow.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inner Mongolia International Mongolian Hospital</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia</state>
        <zip>010065</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wulantuya</last_name>
      <phone>864715182155</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>May 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cerebral Infarction</keyword>
  <keyword>umbilical cord mesenchymal stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

